This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Bactaviva Ab, Thioredoxin Systems Ab. Active years: 2013-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2021
Title: Innovations of Lars Georg Engstrand
Introduction
Lars Georg Engstrand is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of microbiology and pharmacology, holding two patents that address critical health issues. His work focuses on innovative treatments for microbial dysbiosis and the development of antibacterial agents.
Latest Patents
Engstrand's latest patents include "Autologous fecal sample for use in the treatment of microbial dysbiosis." This patent discusses the use of autologous fecal samples obtained from a subject for the prevention and treatment of microbial dysbiosis in the gastrointestinal tract. The disclosed samples are particularly useful for treating dysbiosis associated with various medical conditions, including chronic and infectious diseases.
Another significant patent is "Bacterial thioredoxin reductase inhibitors and methods for use thereof." This invention highlights the mechanism of action of Ebselen, which differentiates between bacterial and mammalian thioredoxin reductase. Ebselen serves as a strong competitive inhibitor of TrxR, making it a promising antibacterial agent, especially against multiresistant strains of bacteria.
Career Highlights
Throughout his career, Engstrand has worked with various companies, including Thioredoxin Systems AB and Bactaviva AB. His innovative research has positioned him as a key figure in the development of new therapeutic strategies.
Collaborations
Engstrand has collaborated with notable scientists such as Arne Holmgren and Jun Lu, contributing to advancements in his field.
Conclusion
Lars Georg Engstrand's contributions to microbiology and pharmacology through his patents demonstrate his commitment to addressing significant health challenges. His innovative approaches continue to influence the development of effective treatments for microbial dysbiosis and bacterial infections.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile